Histone demethylase UTX regulates glioblastoma progression through affecting periostin expression

Yan Luan

Xi'an Jiaotong University

Yingfei Liu

Xi'an Jiaotong University

Jingwen Xue

Xi'an Jiaotong University Medical College First Affiliated Hospital

Ke Wang

Xi'an Jiaotong University Medical College First Affiliated Hospital

Kaige Ma

Xi'an Jiaotong University

Haixia Lu

Xi'an Jiaotong University

Xinlin Chen

Xi'an Jiaotong University

Yong Liu

Xi'an Jiaotong University

Zhichao Zhang (✉ zhangzhichao@xjtu.edu.cn)

Xi'an Jiaotong University <https://orcid.org/0000-0001-7990-101X>

Research Article

Keywords: UTX, Glioblastoma, Tumor progression, Periostin, Patient-derived glioblastoma stem-like cells

Posted Date: February 21st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1299845/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

The histone H3K27 demethylase UTX participates in regulating multiple cancer types. However, less is known about the function of UTX in glioblastoma (GBM), let alone in glioblastoma stem-like cells (GSCs). Our study aims to investigate the functional role and regulatory mechanism of UTX on GBM. By summarizing data from the TCGA database, we showed that UTX expression was significantly increased in GBM and inversely correlated with survival. And knockdown UTX inhibited LN-229 cell (a human GBM cell line) proliferation and promoted apoptosis in a mouse xenograft model. Gene expression profile of UTX knockdown LN-229 cells was analyzed by RNA-seq. The results indicated that the altered genes were strongly associated with tumor progression and the extracellular environment. Bioinformatics and STRING database were used to elucidate the mechanism of UTX and the target gene. Protein-protein interaction analysis periostin (POSTN) protein could interact with most of the other UTX-mediated proteins. More importantly, POSTN supplement abolished the effect of UTX knockdown in GBM cells. Furthermore, silencing UTX exhibited a similar antitumor effect in patient-derived GSCs, while UTX functions were partially restored after exposing POSTN. Our findings suggested that knockdown UTX inhibited GBM progression and tumorigenesis by enhancing the levels of H3K27 methylation in the POSTN gene, thereby suppressing the expression of POSTN and lots of extracellular matrix proteins, providing that UTX might be a vigorous therapeutic strategy for GBM treatment.

Introduction

Glioblastoma (GBM), a WHO grade IV glioma, is the most common primitive malignant brain tumor, characterized by rapid progression, high metastasis and fast relapse [1]. Generally, the treatment for GBM is surgery followed by chemotherapy, radiotherapy or both. Despite the efforts made in recent years, 5-year survival rates for patients with GBM are poor (nearly 3-5%) and the median survival is less than 15 months [2]. In addition, glioblastoma stem-like cells (GSCs) redouble the difficulty of treatment due to the greater resistance to currently antineoplastic agents [3]. A cure for GBM therefore remains elusive. Continuing efforts are in need to explore and develop a novel effective therapeutic target for both GBM and GSCs.

The *Ubiquitously Transcribed Tetra-trico-peptide Repeat on chromosome X* (UTX, also called KDM6A) is a histone demethylase that catalyzes the removal of di- and tri-methyl marks at histone H3 lysine 27 (H3K27) [4]. Previous studies indicated that UTX underpinned a substantial component of epigenetic deregulation and it was strongly associated with multiple types of human cancer [5–7]. UTX inhibited the proliferation, invasion, and metastasis of breast cancer cells by interacting with GATA3 [8]. For lung cancer, UTX deletion dramatically promoted tumorigenesis and progression [9]. In contrast, H3K27 methyltransferase EZH2 has a tumor-promotive effect. It is highly expressed in several forms of cancer and regulates various oncogenic transcription factors, tumor suppressor miRNAs, and cancer-associated non-coding RNA [10]. Although the exact role of UTX in GBM is poorly understood at present, inhibition of JMJD3 (also called KDM6B, an H3K27me3 demethylase) suppressed glioma cell proliferation, migration,

and promoted cell apoptosis [11]. These phenomena suggest UTX might involve in the regulation of GBM progression.

The tumor microenvironment (TME) is comprised by tumor cells, blood vessels, other non-malignant cells, and extra-cellular components [12]. Accumulating evidence suggests that TME is a novel target in tumor therapy [13]. Periostin (POSTN, also known as OSF-2), one of the components of extracellular matrix, belongs to the fasciclin family and is involved in regulating tissue/organ development, pathological fibrosis, tissue remodeling and cancer biology progression [14, 15]. POSTN is secreted by different cells types in solid tumors and exerts its functions through autocrine and paracrine. Secreted POSTN can activate invasion- and survival-related signaling pathways, which in turn promotes invasion, proliferation and survival [16]. For GBM, POSTN expression level was correlated with tumor grade and recurrence. Overexpression of POSTN promoted glioma cell invasion and apoptosis [17]. More importantly, POSTN was among the most upregulated genes in GBM compared to the normal brain tissue [18]. Silencing POSTN in glioma stem cells inhibited cell proliferation and increased survival of xenografts mice [19]. These results suggested that POSTN might be an excellent target for GBM therapeutics. However, the mechanisms of regulation of POSTN expression require further investigation.

In this study, we analyzed the relationship between the expression level of UTX and GBM malignancy. The effects and underlying molecular mechanisms of UTX in both GBM cells and patient-derived GSCs were further investigated. Here we found that high UTX expression promoted both GBM progression and GSCs proliferation. Moreover, our present study may provide evidence that the suppression UTX increased the methylation of H3K27 in the POSTN gene, thereby suppressing POSTN expression which ultimately inhibits growth and tumorigenesis. These results may reveal new insight into the onset of gliomagenesis and progression, provide a vigorous therapeutic strategy for GBM treatment.

Methods

Cell culture

LN-229 cell lines was purchased from American Type Culture Collection (ATCC, USA) ,and U251 MG cell lines was purchased from Procell (China). 1×10^5 cells were seeded in T25 flasks and incubated in an incubator (SANYO, Japan) with 5% CO₂ and 95% air at 37°C. The medium consisted of Dulbecco's Modified Eagle's Medium (DMEM), 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin (all from Gibco, USA). The cell subculture was trypsinized, mechanically blown to create single-cell suspension, and cryopreserved with a liquid nitrogen tank when necessary.

Human glioblastoma stem-like cells (GSCs) were isolated from 3 post-surgical samples (GSC02, GSC05 and GSC08). GSC02 patient underwent surgery at the First Affiliated Hospital of Xi'an Jiaotong University; GSC05 patient underwent surgery at the Second Affiliated Hospital of Xi'an Jiaotong University; GSC08 patient underwent surgery at Shaanxi Provincial Peoples's Hospital. None of the patients received any treatment prior to the intervention. This study was performed in accordance with the principles of the

Declaration of Helsinki. Clinical information and tumor samples were collected with informed consent. The detailed information was shown in Supplementary Table S1. Single GSCs were isolated as previously described and with minor modification [20]. Briefly, after washing 3 times with cold DMEM/F12 (1:1) medium (Gibco), the GBM tissue was cut into small pieces and incubated with dissociation medium (200 μ L Collagenase type I (10 mg / mL, Sigma), 200 μ L Dispase II (20 mg / mL, Sigma) and 1.6 mL DMEM/F12 (1:1) medium) at 37°C for 12 min. Then, the tissue was mechanically dissociated using a pipette and filtered using a 40 μ m cell strainer (BD Falcon), followed by centrifugation at 1,000 rpm for 3 min. Cells were seeded at 200,000 cell/ml in non-adhesive T25 flasks with 5 mL complete medium, consisted of DMEM/F12 (1:1), 1% N2, 2% B27 (minus vitamin A), 20 ng/mL EGF, and 10 ng/mL bFGF. After culturing 5-7 days, the formation of 80-200 μ M sphere was observed. For single-cell adhesive culture, the sphere was dissociated into single cells using ACCUTASE™ (Stemcell Technologies, Canada) and plated in poly-D-lysine-coated 24-well plates.

Public data sets analysis

The TPM (transcripts per million reads) of UTX from TCGA cancers and matched TCGA normal and GETx data were visualized by GEPIA2 (<http://gepia2.cancer-pku.cn/#analysis>). For survival analyses, Hazard ratios (HR) and Kaplan–Meier plots were determined using GEPIA 2 (<http://gepia2.cancer-pku.cn/#survival>) based on the expression status of UTX in TCGA data sets.

UTX knockdown treatment

The small interfering RNA (siRNA) specific to human UTX and scrambled siRNA negative control (siNC) were synthesized by Genechem (Shanghai, China). The sequences were as follows:

si-UTX-1: 5'-AUUUCAGUGGGCUAUUAAATT-3',

si-UTX-2: 5'-ACGAAUAUCAAGGUUUCATT-3',

si-UTX-3: 5'-CUAUGGAUGCUUUGCAAGCTT-3',

siNC: 5'-UUCUCCGAACGUGUCACGUTT-3'.

LN-229 and U251 MG cells were grown on 24-well plates, and Lipofectamine 2000 reagent (Invitrogen) was used to deliver the siRNA (100 nM). The knockdown efficiency was evaluated by RT-PCR and Western blot. The lentivirus vector containing shRNA targeting human UTX (shUTX) or negative control vectors (shNC) was purchased from Genechem (Shanghai, China). Two shNC lentivirus vectors were used in this study; one containing eGFP was used to measure transfection efficiency, and the other which did not express fluorescent protein was used for the majority of the subsequent experiment. (2×10^4 cells/well) were seeded in a 24-well plate and infected with 2 μ L shUTX (1×10^8 virus, MOI = 1:10) or 1 μ L shNC (1×10^8 virus, MOI = 1:5), respectively.

One day later, the infected cells were selected with puromycin at 24 hours. For the GBM cells, the concentration of puromycin was 2.5 μ g/ml, and 1.6 μ g/ml puromycin was used for GSCs.

Immunostaining

Cells were plated onto the coverslips and fixed with 4% paraformaldehyde (PFA) at room temperature for 20 min followed by washing three times with PBS. Then, cells were permeabilized in 0.1% Triton X-100 for 15 min and blocked with blocking buffer (containing 5% bovine serum albumin and 5% horse serum in PBS) for 1 h, followed by incubating with the primary antibodies overnight at 4°C. After washing three times with PBS, cells were then incubated with suitable secondary antibodies. The information of the first and secondary antibodies were shown in Supplementary Table S2. The negative control samples were just incubated in the blocking buffer instead of the primary antibody. Nuclei were visualized with DAPI-containing mounting medium (Vector, USA). Images were acquired using a fluorescence microscope equipped with a digital camera (BX51 + DP71, Olympus, Japan) and analyzed with ImageJ software (NIH, USA). The sphere formation images were taken with a Leica SP8 confocal microscope equipped with a × 40 oil immersion lens.

Flow cytometry analysis

For cell cycle analysis, the treated cells were dissociated with trypsin into single cells and fixed with pre-cooling 75% ethanol overnight at 4°C. After washing twice with PBS, cells were stained with Propidium Iodide solution (100 µg/mL, Sigma-Aldrich, USA) containing 100 µg/mL RNase A (New England Biolabs, USA) for 15 min at 37°C and away from light. The cell cycle analysis was performed using a FACSCalibur system (BD Biosciences, USA) with an excitation at 488 nm and emission at 630 nm. 1×10^5 cells were detected for each sample. The data were collected using the FACSsortCellquest software (BD Biosciences), and the DNA content and cell cycle distribution were determined using the Modfit LT software (BD Biosciences). The proliferation index was used to evaluate the changes in the cell cycle distribution with the following formula: $\text{proliferation index} = (S+G2/M) / (G0/G1+S+G2/M)$.

Apoptosis analysis was performed using the FITC Annexin V apoptosis detection kit (BD Biosciences, USA). After treatment, cells were dissociated into single cells, washed twice with pre-cooling PBS and resuspended in 1 × binding buffer. Then, 200 µL of the cell suspension (more than 1×10^5 cells) was transferred to a 5 mL FACS tube (BD Biosciences) and stained in duplicate with 10 µL of FITC Annexin V conjugate and 10 µL of propidium iodide (PI, 10 mg/mL) for 15 min in dark at room temperature. Apoptosis was analyzed using a FACSCalibur (BD Biosciences) with 488 nm excitation for Annexin V (emission collected at 525 nm) and 488 nm excitation for PI (emission collected at 630 nm). The data were collected with FACSsort Cellquest software (BD Biosciences) and the percent of apoptotic cells was referred to the apoptotic index with the following formula: $(LR+UR) / (UL+LL+LR+UR)$. Apoptosis was analyzed using a FACSCalibur (BD Biosciences) with 488 nm excitation for Annexin V (emission collected at 525 nm) and 488 nm excitation for PI (emission collected at 630 nm). The data were collected with FACSsort Cellquest software (BD Biosciences) and the percent of apoptotic cells was referred to the apoptotic index with the following formula: $(LR+UR) / (UL+LL+LR+UR)$.

TUNEL assay

The terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was used for detecting cell apoptosis according to the manufacturer's instructions (Roche Diagnostics, USA). In brief, cells were fixed with 4% PFA for 30 min, followed by permeabilization using 0.1% Triton X-100 in 0.1% sodium citrate buffer for 2 min on ice. Then, cells were incubated with 50 μ L TUNEL reaction mixture for 1 h at 37°C. After washing with PBS, nuclei were stained with DAPI-containing mounting medium (Vector). Images were acquired using a fluorescence microscope equipped with a 40 $\times$ objective (BX51 + DP71, Olympus) and analyzed with an Image-Pro Plus 5.0 software (Media Cybernetics, USA).

BrdU labeling

Following the treatment, GBM cells were incubated with 10 μ g/mL of BrdU for 1 hour, and GSCs were treated with BrdU for 2 hours. The BrdU-labeled cells were further detected by immunostaining. To identify the BrdU-labeled cells, cells were pretreated with 2 N HCl for 30 min at 37°C, followed by neutralizing with 0.1 M borate buffer (pH8.5) for 15 min. The percentage of labeled cells was evaluated and normalized by the PI-stained nuclei or SOX2 positive cells.

Western blot analysis

After the treatment, cells or tissues were collected and lysed in RIPA lysis buffer supplemented with Protease Inhibitor Cocktail (Roche, Germany) for 15 min on ice, followed by sonication (Sonics, USA) and centrifugation (Eppendorf, Germany). Then supernatants were collected, and protein concentration of the samples was measured using the BCA assay (Pierce, USA). After boiling with loading buffer, Proteins (20 μ g – 40 μ g depending on the target protein) were resolved by 10%-12% SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes (BioRad, USA). The membranes were blocked with 5% non-fat milk for 2 h at RT and subsequently probed with specific primary antibodies overnight at 4°C (Supplementary Table S2). After washing three times with TBST, the membranes were incubated with horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG for 2 h at room temperature. Then, immunoreactive bands were visualized with an enhanced chemiluminescent substrate according to the manufacturer's protocol (Pierce). The bands were collected using GeneGnomeXRQ (Syngene, UK) and analyzed using the ImageJ 3.5 software. The expression levels of target proteins were determined and normalized to the housekeeping β -Actin. All Western blot data were presented in samples from at least 3 independent experiments.

Colony formation assay

Cells (500 cells/well) were seeded into a six-well plate and cultured in the normal condition for 14 days. After fixation with 4% PFA, cells were stained with crystal violet solution. The number of colonies was counted for each sample and data were presented in samples from at least 3 independent experiments.

Wound healing (scratch) assay

Single GBM cells (2×10^5 /well) were seeded in a six-well plate and grown to full confluency and growth arrested. The scratch a straight line in one direction scratches were made using a p200 pipet tip and monitored after 24 h. Cell migration ability was evaluated by considering the percentage of wound

closure. The photographs from randomly selected fields were taken using an inverted phase-contrast microscope (Olympus, Japan). The gap distance of the wound was measured by Image-Pro Plus 5.0 software, and these assays were performed three times.

Transwell invasion analysis

The 8 μm transwell invasion chambers (Millipore) were pre-coated with 100 μL Matrigel (BD Biosciences). 2×10^4 of Cells suspension were added in the upper Matrigel-coated chambers; 600 μL DMEM containing 10% FBS was filled with in the lower wells. After incubation for 24 h, cells were fixed and stained with 0.5% violet crystal, and then cells on the upper portion of the membrane were removed with a cotton swab. The number of invaded cells was counted under a light microscope, and the data were normalized to the average of the control.

Animal experiments

Pathogen-free male athymic BALB/c nude mice (5 weeks old) weighing 20-25 g were used for this study and all mouse experiments were approved by the Xi'an Jiaotong University Health Science Center Ethics Committee. The mice were purchased from the Xi'an Jiaotong University Laboratory Animal Center (Certificate No. 22-9601018). The staff at Xi'an Jiaotong University Laboratory Animal Center was responsible for housing and daily maintenance. Housing and environmental enrichment are according to standards. All efforts were undertaken to minimize the suffering of the mice. 100 μL of Normal LN229 (Blank), sh-NC-LN229 (shNC) or KD-UTX-LN229 (KD-UTX) suspension (1×10^7 / mL) were implanted into the subcutis of the mice to establish the heterotopic xenograft model. Tumors were monitored every weekday and size was measured by using an electronic digital caliper. If the tumor size exceeds 2000 mm^3 or the diameter exceeds 15 mm, the mice will be weeded out and euthanatized. Five mice were sacrificed at 3 d, 7 d, 14 d, and 28 d respectively. At each time point, tumors were isolated and tumor weight was measured, and tumor size was calculated by the formula: $\text{length} \times \text{width}^2 \times 0.52$ [21]. Subsequently, heterotopic tumor tissues were collected and used for Western bolt and ELISA analysis.

RNA-sequencing (RNA-seq)

Total RNA was extracted using a Trizolreagent kit (Invitrogen) according to the manufacturer's protocol. RNA quality was assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) and checked using RNase-free agarose gel electrophoresis. Eukaryotic mRNA was enriched by Oligo(dT) beads, while prokaryotic mRNA was enriched by removing rRNA by Ribo-ZeroTM Magnetic Kit (Epicentre, Madison, USA). Then the enriched mRNA was fragmented into short fragments using fragmentation buffer and reverse transcribed into cDNA with random primers. Second-strand cDNA was synthesized by DNA polymerase I, RNase H, dNTP and buffer. Then the cDNA fragments were purified with QiaQuick PCR extraction kit (Qiagen, The Netherlands), end-repaired, poly(A) added, and ligated to Illumina sequencing adapters. The ligation products were size selected by agarose gel electrophoresis, amplified by PCR and sequenced using Illumina HiSeq2500 by Gene Denovo Biotechnology Co. (Guangzhou, China). Raw data of RNA-seq reported in this study have been deposited in the Genome Sequence Archive (GSA) in BIG Data Center (<https://ngdc.cncb.ac.cn/gsa-human/>) under the accession number HRA001073.

Bioinformatic analysis was performed using Omicsmart, a real-time interactive online platform for data analysis (<http://www.omicsmart.com>).

Quantitative reverse-transcription PCR (qRT-PCR)

Total RNA was isolated from cells using Trizol reagent following the manufacturer's instructions, and 2 µg RNA was reverse transcribed into cDNA using a RevertAid first-strand cDNA synthesis kit (ThermoFisher, USA) supplemented with Oligo(dT)18 and Random Hexamer Primer. qRT-PCR was performed with GoTaq® qPCR Master Mix (Promega, USA) using an iQ5 Real-Time PCR Detection System (BioRad, USA). The primer pairs were synthesized by TaKaRa and displayed in Supplementary Table S3.

Chromatin Immunoprecipitation (ChIP)-qPCR

ChIP was performed as previously described with minor modifications as detailed below [22]. 100 µL single-cell suspensions (2×10^7 / mL) were fixed by 1% formaldehyde for 10 min. Then, glycine solution (final concentration 125 mM) was added and incubated for 5 min. After twice washing with 500 µL ice-cold PBS, 300 µL lysis buffer were added and sonicated for 3×30 s using VCX 500 (SONICS, USA). The lysate was diluted and incubated in Dynabeads™ Protein A (Invitrogen, USA) which had pre-incubated with 2 µg of H3K27me2/me3 antibody (39435, Active Motif, USA) or IgG (Abcam, UK). The immune complexes were incubated at 4°C, 20 rpm on a Tube Revolver Rotator for 12 hours. Then, the chromatin–antibody–bead complexes were washed 4 times in 100 µL ice-cold RIPA buffer, rinsed with 400 µL ChIP elution buffer (containing 50 µg RNase A) and incubated at 37°C at 1,200 rpm on a Thermomixer (Eppendorf, Germany) for 1 h followed by incubating with 2 µL Proteinase K (New England Biolabs, USA) at 65°C, 4 hours. An input control was processed in parallel. ChIP DNA was purified by phenol-chloroform isoamyl alcohol extraction, ethanol-precipitated and dissolved in 20 µL EB buffer (Qiagen, Germany). Analysis of DNA was performed using qRT-PCR with gene-specific primers Supplementary Table S4). Recovery of genomic DNA as the percentage input was calculated as the ratio of immunoprecipitate to input.

The enzyme-linked immunosorbent assay (ELISA)

At the end of each time point, the cell culture medium was collected and analyzed using the POSTN, VCAM1 and Pro-Collagen I alpha 1 ELISA kit (R&D Systems) according to the manufacturer's instructions. The absorbance was measured at 450 nm using a multimicroplate spectrophotometer (BioTek). Triplicate parallel wells were examined in all the experiments and the data were presented as the average of at least three independent experiments.

Cell viability assay

Cell viability was evaluated using the Cell Counting Kit-8 (CCK-8; 7sea, Shanghai, China) assay. Cells were grown in 96-well plates at 5,000 cells/well and cultured for 1, 2, 3, 5 and 7 days. At the end of each treatment, 20 µl/well of CCK-8 was added to the media and cells were incubated for 2 hr at 37°C. The absorbance was measured at 490 nm using a multimicroplate spectrophotometer (BioTek, Winooski, VT).

Triplicate parallel wells were examined in all the experiments, and the data were collected as the average of at least three independent experiments. The results are presented as the absorbance value.

Statistical Analysis

Statistical analyses were performed using the GraphPad Prism 5.0 software. Data were evaluated for normality and homogeneity of variance before comparison. Differences between groups were analyzed using one-way ANOVA, followed by Tukey's post hoc test. The Kolmogorov-Smirnov test was used for normality and homogeneity. The data were shown as mean $\pm$ standard deviation, and $P < 0.05$ was considered as statistically significant difference.

Results

UTX knockdown restricts GBM growth in a mouse xenograft model

The GEPIA2 databases (including normal, low-grade glioma (LGG) and glioblastoma multiform samples) was used to analyze the differential expression of UTX. Compared to the normal group, the UTX expression level was significantly increased in GBM and oligodendrogliomas (ODs, a subcategory of LGG) (Fig. 1A, B). Moreover, UTX expression was negatively correlated with overall survival for LGG and GBM patients (Fig. 1C). These results suggested that UTX was a risk factor and blockade of UTX expression might be developed for GBM treatment.

To unambiguously define the role of UTX in GBM, we first suppressed UTX expression by RNA interference (RNAi). LN-229 cells (a human GBM cell line) were transfected with three UTX-target siRNAs (si-UTX-1/2/3). The combined results from RT-PCR and Western blot indicated that si-UTX-1 exerted a higher inhibition efficiency (Fig. S1 A, B, E). Therefore, the si-UTX-1 sequence was used in the subsequent lentiviral packaging. The lentivirus-transduced cells were selected using puromycin. We found that the vast majority of cells expressed eGFP and the expression of UTX was significantly decreased (Fig. S1 F-H, J). This lentiviral UTX shRNA (KD-UTX) was used for further experiments. To explore the cellular function of UTX in GBM, the stable UTX knockdown LN229 cells were implanted into the subcutis of the athymic nude mice to establish the heterotopic xenograft model. We measured the tumor volumes and weights, detected the expression of apoptosis related Caspase-3 and Cyclin D1 at different time points. Tumor volumes and weights were significantly decreased in the LN229-KD-UTX group (Fig. 1D-F). Furthermore, we found Cleaved-caspase-3 / Pro-caspase-3 ratio was increased, while the expression of CyclinD1 was decreased (Fig. 1G-I). Taken together, these data strongly suggest that silencing UTX can inhibit GBM progress via attenuating cell proliferation and promoting apoptosis.

UTX is closely related to GBM progression

In order to understand the molecular insights by which UTX exerts its effects, we performed whole-transcriptome sequencing analysis of LN-229 cells after culturing 3 days. Principal component analyses

(PCA) showed that the transcriptome of UTX knockdown cells was clearly segregated from the shNC group (Fig. 2A). 469 genes expression were significantly altered by UTX withdrawal. Of these, 374 genes expression increased, while 95 genes decreased (Fig. 2B; Fig. S2 A, B). Geneset enrichment analysis (GSEA) showed DNA replication (Fig. 2C), cell cycle checkpoint (Fig. 2D), G1/S and G2/M phase transition genes (Fig. 2E, F) were significantly enriched in the downregulated genes. Gene Ontology (GO) enrichment analysis showed that most of the altered genes were preferentially correlated with secretion, extracellular matrix and extracellular structure organization (Fig. 2G). We also examined the UTX function using Disease Ontology (DO) (Fig. 2. H) and KEGG databases (Fig. 2I). The results showed that the changes in gene expression were closely associated with cancers and involved in the regulation of cell growth and death. Collectively these results suggest the UTX knockdown impairs the proliferation of GBM cells.

UTX knockdown affects many extracellular matrix proteins expression

UTX is linked with the demethylation of lysine residues on H3K27, and H3K27me_{2/3} is usually associated with gene repression. Therefore, we focused on the 95 downregulated genes. The significantly (>1.5 fold) downregulated genes were selected and qRT-PCR was carried out to validate the sequencing results. Most qRT-PCR results of the genes were consistent with that of RNA-seq (Fig. 3A), while the expression of some genes was not significantly decreased or slightly increased (Fig. S2 C). Then, ChIP-qPCR was carried out to confirm the downregulated genes which were regulated directly by H3K27me_{2/3}. The results revealed that the level of H3K27me_{2/3} was increased in 15 genes (Fig. 3B). Interestingly, most of these genes, including POSTN, VCAM1 and COL1A1, are primarily responsible for encoding secreted proteins that in turn modulate the extracellular microenvironment. In order to give more reliable results we used two human GBM cell lines (LN-229 and U251 MG) for further studies. The KD-UTX lentivirus also could inhibit UTX expression in U251 MG cells (Fig. S1 C, D, I). Then, we detected the level of H3K27me_{2/3} by Western blot. As expected, the level of H3K27me_{2/3} was significantly increased in the KD-UTX group (Fig. 3C, D). To further investigate the effect of UTX on the expression of extracellular matrix protein and intracellular protein were detected by ELISA and Western blot, respectively. POSTN, COL1A1 and VCAM1 concentrations in the culture medium were significantly decreased after UTX knockdown treatment (Fig. 3E, F). Western blot assay showed that the levels of intracellular proteins (including POSTN, COL1A1, PTHLH, VCAM1 and CPA4) were reduced as well in the KD-UTX group (Fig. 3G-I). The above results indicate that the effect of UTX on GBM cells may be mediated through regulating the tumor microenvironment.

POSTN is involved in the regulation of UTX on GBM progression

The proteins, which are regulated by H3K27me_{2/3}, were analyzed by the STRING database to reveal protein-protein connections. We found that POSTN protein could interact with various proteins and might

play a pivotal role in the transcriptional regulatory network (Fig. 4A, B). To evaluate the involvement of POSTN in the regulation of UTX on GBM progression, 2 µg/mL recombinant human POSTN protein (R&D Systems, USA) was replenished in the KD-UTX cell culture medium. The proliferation effect of UTX on GBM was verified by BrdU incorporation and cell cycle analysis. The results showed that UTX knockdown significantly decreased the number of BrdU-positive cells and proliferation index. And supplement POSTN protein in the medium abolished the effect of UTX knockdown (Fig. 4C-H). To further verify the role of UTX in GBM cell proliferation, we performed a colony formation assay to investigate the long-term effect of UTX on proliferation. As we except, the colony-forming ability was decreased in the KD-UTX group, and addition of POSTN protein partially restored the inhibitory effect of UTX knockdown on proliferation (Fig. 4I-K). TUNEL staining and flow cytometry with Annexin V/PI were applied to distinguish apoptotic cells. There was an increase in both the number of TUNEL-positive cells and the apoptosis rate following UTX knockdown treatment. POSTN protein eliminated the pro-apoptotic effect of UTX knockdown in both LN-229 and U251 MG cells (Fig. 5A-F). Then, wound healing and transwell invasion assay were used to detect the migration and invasion abilities in GBM cells, respectively. Wound healing assay showed that UTX knockdown markedly attenuated the migration capacity of LN229 and U251 MG cells (Fig. 5G-I). Similar to the wound healing assay, the number of transwell invasive cells was significantly decreased by suppressing the UTX expression in GBM cells (Fig. 5J-L). However, the effect of UTX on migration and invasion was abolished after exposing POSTN. The aggregate of the above results were consistent with the in vivo data, suggesting that knockdown UTX promoted GBM progression by inhibiting POSTN expression.

UTX knockdown influences proliferation and apoptosis of patient-derived GSCs by regulating POSTN expression

Previous studies demonstrated that POSTN played a crucial role in maintaining cancer stem cells and promoting tumor progression, including growth, invasion and metastasis [23, 24]. In the present study, we investigated whether UTX participates in regulating GSCs. At first, we isolated and cultured patient-derived GSCs. Human GSCs were isolated from three post-surgical patients (GSC02, GSC05 and GSC08). After culturing 5-7 days, 80-200 µM spheres were formed (Fig. 6A). The double immunofluorescent staining showed that these spheres expressed cancer stem cell markers, including CD133, CD15, CD44 and nestin (Fig. 6B, C). Moreover, the single-GSCs staining showed that 96.89% ± 5.37% nestin-positive cells, of which 96.65% ± 4.28% expressed SOX2 (Fig. 7D). These phenomena suggested that these cultured cells were human GSCs, and these cells were used to conduct subsequent experiments. After infecting with KD-UTX lentivirus, the UTX expression was significantly decreased in the patient-derived GSCs (Fig. S3 A, B). Moreover, silencing UTX inhibited POSTN protein (Fig. S3 C, D) and mRNA expression (Fig. S3 E) while enhancing the level of H3K27me2/3 (Fig. S3 F). These results indicated that UTX regulated POSTN expression through altering H3K27 methylation levels in the patient-derived GSCs. To confirm the effect of UTX on GSCs, we measured cell viability by CCK-8 assay at different time-points. The results showed that low UTX expression in GSCs was characterized by a low proliferation rate (Fig. 6E-G). Moreover, suppression of UTX resulted in a decreased number of BrdU-labelled cells (Fig. 6H,

G; Fig. S4 A, C and E). In contrast, UTX knockdown significantly increased the TUNEL positive cells (Fig. 6I, K; Fig. S4 B, D and F). Interestingly, supplement POSTN in the medium abolished the effect of UTX on proliferation and apoptosis in GSCs. These data suggest that UTX can regulate the proliferation and apoptosis of the patient-derived GSCs by regulating POSTN expression.

Discussion

In this study, we showed that UTX expression was significantly elevated in GBM and was inversely correlated with survival. Knockdown UTX in both GBM cells and patient-derived GSCs increased the methylation of H3K27 in the POSTN gene, thereby suppressing POSTN expression. The low expression level of POSTN affected lots of extracellular components (including COL1A1, VCAM1, PTHLH, and CPA4), which in turn inhibited growth and tumorigenesis (Fig. 7). These results suggested that UTX was an oncogenic factor and could promote growth and tumorigenesis, and UTX inhibition was a novel therapeutic target for rational GBM drug development. However, targeting UTX for cancer treatment remains controversial. Although lots of studies have provided evidence to show that UTX plays a pro-oncogenic role [25], some studies have reported the role of UTX as a tumor suppressor [26, 27]. We showed that UTX is differentially expressed in a variety of tumors (Fig. S5 A, B). This large difference may, in part, be responsible for the differences in the effect of UTX among different cancer types. Another reason may be that UTX is a subunit of MLL3 and MLL4, which are the members of the COMPASS family of histone H3 lysine 4 (H3K4) methyltransferases [28]. Compared to the UTX, H3K4 methylation has the opposite effect on the regulation of gene expression [29]. H3K4 methylation is tightly associated with transcriptional start sites of actively transcribed genes [30]. The biological role of UTX and MLL3/MLL4 in cancer pathogenesis is quite complicated. The mechanistic relationship between UTX and MLL3/MLL4 and their regulation of enhancer activity, whether local or global is still unclear. Our research indicated that these chromatin proteins in the regulation of enhancer activity are not global in GBM, just few tumor suppressor genes were activated by UTX. Further studies are necessary to understand the fundamental mechanism and precise functional impact of MLL3/MLL4 and UTX alterations.

The TME is a dynamic network structure and has emerged as a key factor to regulate tumor progression [31, 32]. Therefore, anticancer research cannot be just understood the features of cancer cells, but instead should encompass the effect of the TME [33]. In this study, GO enrichment analysis showed that the genes of secretion, extracellular structure and matrix had changed after UTX knockdown. And a large number of ECM genes, including COL1A1, POSTN, VCAM1, PTHLH, and CPA4, actually changed which was detected by qRT-PCR, ELISA and Western blotting. These phenomena suggested that UTX mainly regulated GBM through alteration in the ECM. More importantly, protein-protein interactome analysis showed that POSTN protein could interact with most other proteins. As one of the matricellular proteins, POSTN is mainly secreted by stromal cells in normal tissues. But tumor cells, especially cancer stem cells, can also secrete POSTN in solid tumors [34]. POSTN has played a vital role in regulating tumor progression and tumorigenesis through remodeling various tumor microenvironments, such as cancer stem cell niche, perivascular niche, immunosuppressive microenvironment [35–38]. In this study, we demonstrated that replenishment of POSTN protein in the medium abolished the effect of UTX on

proliferation and apoptosis in both GBM cells and patient-derived GSCs. These phenomena suggested that POSTN was a key regulator of the antitumor effect of UTX knockdown on GBM. However, the antitumor effect of UTX cannot simply account for the inhibition of POSTN expression. Many other tumor-associated proteins like EREG, ECSCR, STC2 and MPP4 were also regulated by UTX, we cannot rule out the effect of these proteins. Whether these proteins mediate the antitumor mechanism remains to be seen.

As the most malignant and prevalent primary brain tumor, GBM is a complex system and represents heterogeneity. Some with increased carcinogenicity, unlimited self-renewal potential, a higher capacity of stemness [39]. These stem-like cells were considered as GSCs, one of the important origins of GBM relapse [40, 41]. Previous research demonstrated that GSCs displayed higher intrinsic chemo- and radioresistance [42]. Moreover, there is increasing evidence that chemoresistance and tumor recurrence are closely related to GSCs [43]. Therefore, a novel investigation of eradicating the GSCs is a therapeutic priority for GBM treatment. Our study showed that UTX knockdown inhibited proliferation while promoting the apoptosis of patient-derived GSCs. Remarkably, supplemental POSTN protein could partially abolish the effect of UTX on GSCs. It provided further evidence that UTX could be regarded as a novel and effective therapeutic target for GBM. Compared to the GSCs which sorting from cell lines, the patient-derived GSCs represent a more realistic response in terms of recapitulating the individual differences [44]. In this study, we used patient-derived GSCs to examine UTX functions, and this enhances the trustworthiness of our findings.

Tumor initiation and progression is a very complex process, genetic and epigenetic alterations are both associated with carcinogenesis [45]. The great potential for epigenetic regulation by histone methylation lies in the fact that histone methylation changes are reversible, allowing recovery of gene function with normal DNA sequences [46]. Our current study set out to investigate the impact of UTX on both GBM and GSCs progression and suggested that knockdown UTX exerted an anti-tumor effect on GBM. These results add to the rapidly expanding field of the effect of UTX and may contribute to the development of therapeutic strategies for GBM. However, additional research, especially using clinical samples, is necessary for an in-depth understanding of the precise mechanisms of UTX in GBM.

Declarations

Acknowledgements

The authors are grateful to Dr. Jia Wang, Dr. Zhenyu Guo and Dr Xingyu Miao for providing the technical support to carry out this work.

Author Contributions

ZC. Zhang designed the experiments. XL. Chen, HX. Lu, ZC. Zhang, and Y. Liu supervised the research. JW. Xue and K. Wang performed animal breeding. Y. Luan and YF. Liu performed most of the other experiments. Z. Zhang prepared manuscript drafts. KG. Ma and Y. Liu edited the paper.

Funding

This work was supported by grants from National Natural Science Foundation of China (No. 81901156, 82001493); China Postdoctoral Science Foundation (2017M623152, 2018T111035, 2019M653662). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data Availability

Raw data of RNA-seq reported in this study have been deposited in the Genome Sequence Archive (GSA) in BIG Data Center (<https://ngdc.cncb.ac.cn/gsa-human/>) under the accession number HRA001073. All other data supporting the findings of this study are available within the article and the supplemental information, or from the corresponding author upon reasonable request

Ethical Approval

Clinical information and samples were obtained with informed consent. Patient-derived cell culture and all mouse experiments were approved by the Xi'an Jiaotong University Health Science Center Ethics Committee (No. 2021-1607). This study conforms to the Declaration of Helsinki.

Consent to Participate

The informed consent was received from all subjects.

Consent for Publication

All authors consent to publication of this manuscript.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Davis ME (2016) Glioblastoma: Overview of Disease and Treatment. Clin J Oncol Nurs 20(5 Suppl):S2–8. doi:10.1188/16.CJON.S1.2-8
2. Shergalis A, Bankhead A 3, Luesakul U, Muangsin N, Neamati N (2018) Current Challenges and Opportunities in Treating Glioblastoma. Pharmacol Rev 70(3):412–445. doi:10.1124/pr.117.014944
3. Dirkse A, Golebiewska A, Buder T, Nazarov PV, Muller A, Poovathingal S, Brons NHC, Leite S, Sauvageot N, Sarkisjan D, Seyfrid M, Fritah S, Stieber D, Michelucci A, Hertel F, Herold-Mende C, Azuaje F, Skupin A, Bjerkvig R, Deutsch A, Voss-Bohme A, Niclou SP (2019) Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nat Commun 10(1):1787. doi:10.1038/s41467-019-09853-z

4. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Canaani E, Salcini AE, Helin K (2007) UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. *Nature* 449(7163):731–734. doi:10.1038/nature06145
5. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, Edkins S, Hardy C, O'Meara S, Teague J, Butler A, Hinton J, Latimer C, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Cole J, Forbes S, Jia M, Jones D, Kok CY, Leroy C, Lin ML, McBride DJ, Maddison M, Maquire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, Pleasance E, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turner R, Turrell K, Varian J, West S, Widaa S, Wray P, Collins VP, Ichimura K, Law S, Wong J, Yuen ST, Leung SY, Tonon G, DePinho RA, Tai YT, Anderson KC, Kahnoski RJ, Massie A, Khoo SK, Teh BT, Stratton MR, Futreal PA (2009) Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. *Nat Genet* 41(5):521–523. doi:10.1038/ng.349
6. Kobatake K, Ikeda KI, Nakata Y, Yamasaki N, Ueda T, Kanai A, Sentani K, Sera Y, Hayashi T, Koizumi M, Miyakawa Y, Inaba T, Sotomaru Y, Kaminuma O, Ichinohe T, Honda ZI, Yasui W, Horie S, Black PC, Matsubara A, Honda H (2020) Kdm6a Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with p53 Dysfunction. *Clin Cancer Res* 26(8):2065–2079. doi:10.1158/1078-0432.CCR-19-2230
7. Leng X, Wang J, An N, Wang X, Sun Y, Chen Z (2020) Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3. *Oncogene* 39(41):6468–6479. doi:10.1038/s41388-020-01449-y
8. Yu W, Huang W, Yang Y, Qiu R, Zeng Y, Hou Y, Sun G, Shi H, Leng S, Feng D, Chen Y, Wang S, Teng X, Yu H, Wang Y (2019) GATA3 recruits UTX for gene transcriptional activation to suppress metastasis of breast cancer. *Cell Death Dis* 10(11):832. doi:10.1038/s41419-019-2062-7
9. Wu Q, Tian Y, Zhang J, Tong X, Huang H, Li S, Zhao H, Tang Y, Yuan C, Wang K, Fang Z, Gao L, Hu X, Li F, Qin Z, Yao S, Chen T, Chen H, Zhang G, Liu W, Sun Y, Chen L, Wong KK, Ge K, Chen L, Ji H (2018) In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. *Proc Natl Acad Sci U S A* 115(17):E3978–E3986. doi:10.1073/pnas.1716589115
10. Yamaguchi H, Hung MC (2014) Regulation and Role of EZH2 in Cancer. *Cancer Res Treat* 46(3):209–222. doi:10.4143/crt.2014.46.3.209
11. Sui A, Xu Y, Li Y, Hu Q, Wang Z, Zhang H, Yang J, Guo X, Zhao W (2017) The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells. *Oncotarget* 8(40):68591–68598. doi:10.18632/oncotarget.19793
12. Wu T, Dai Y (2017) Tumor microenvironment and therapeutic response. *Cancer Lett* 387:61–68. doi:10.1016/j.canlet.2016.01.043
13. Allegrezza MJ, Conejo-Garcia JR (2017) Targeted Therapy and Immunosuppression in the Tumor Microenvironment. *Trends Cancer* 3(1):19–27. doi:10.1016/j.trecan.2016.11.009
14. Izuhara K, Arima K, Ohta S, Suzuki S, Inamitsu M, Yamamoto K (2014) Periostin in Allergic Inflammation. *Allergol Int* 63(2):143–151. doi:10.2332/allergolint.13-RAI-0663

15. Li W, Gao P, Zhi Y, Xu W, Wu Y, Yin J, Zhang J (2015) Periostin: its role in asthma and its potential as a diagnostic or therapeutic target. *Respir Res* 16:57. doi:10.1186/s12931-015-0218-2
16. Ruan K, Bao S, Ouyang G (2009) The multifaceted role of periostin in tumorigenesis. *Cell Mol Life Sci* 66(14):2219–2230. doi:10.1007/s00018-009-0013-7
17. Mikheev AM, Mikheeva SA, Trister AD, Tokita MJ, Emerson SN, Parada CA, Born DE, Carnemolla B, Frankel S, Kim DH, Oxford RG, Kosai Y, Tozer-Fink KR, Manning TC, Silber JR, Rostomily RC (2015) Periostin is a novel therapeutic target that predicts and regulates glioma malignancy. *Neuro Oncol* 17(3):372–382. doi:10.1093/neuonc/nou161
18. Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liao LM, Nelson SF (2006) Primary glioblastomas express mesenchymal stem-like properties. *Mol Cancer Res* 4(9):607–619. doi:10.1158/1541-7786.MCR-06-0005
19. Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, Rich JN, Bao S (2015) Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. *Nat Cell Biol* 17(2):170–182. doi:10.1038/ncb3090
20. Azari H, Millette S, Ansari S, Rahman M, Deleyrolle LP, Reynolds BA (2011) Isolation and Expansion of Human Glioblastoma Multiforme Tumor Cells Using the Neurosphere Assay. *Jove-J Vis Exp*(56). doi:ARTN e3633 3791/3633
21. Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. *Cancer Chemother Pharmacol* 24(3):148–154. doi:10.1007/BF00300234
22. Lim DA, Huang YC, Swigut T, Mirick AL, Garcia-Verdugo JM, Wysocka J, Ernst P, Alvarez-Buylla A (2009) Chromatin remodelling factor Mll1 is essential for neurogenesis from postnatal neural stem cells. *Nature* 458(7237):529–533. doi:10.1038/nature07726
23. Michaylira CZ, Wong GS, Miller CG, Gutierrez CM, Nakagawa H, Hammond R, Klein-Szanto AJ, Lee JS, Kim SB, Herlyn M, Diehl JA, Gimotty P, Rustgi AK (2010) Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. *Cancer Res* 70(13):5281–5292. doi:10.1158/0008-5472.CAN-10-0704
24. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD (2002) Periostin secreted by epithelial ovarian carcinoma is a ligand for $\alpha(V)\beta(3)$ and $\alpha(V)\beta(5)$ integrins and promotes cell motility. *Cancer Res* 62(18):5358–5364
25. Kaneko S, Li X (2018) X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism. *Sci Adv* 4(6):eaar5598. doi:10.1126/sciadv.aar5598
26. Ntziachristos P, Tsirigos A, Welstead GG, Trimarchi T, Bakogianni S, Xu L, Loizou E, Holmfeldt L, Strikoudis A, King B, Mullenders J, Becksfort J, Nedjic J, Paietta E, Tallman MS, Rowe JM, Tonon G, Satoh T, Kruidenier L, Prinjha R, Akira S, Van Vlierberghe P, Ferrando AA, Jaenisch R, Mullighan CG, Aifantis I (2014) Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. *Nature* 514(7523):513–517. doi:10.1038/nature13605
27. Xie G, Liu X, Zhang Y, Li W, Liu S, Chen Z, Xu B, Yang J, He L, Zhang Z, Jin T, Yi X, Sun L, Shang Y, Liang J (2017) UTX promotes hormonally responsive breast carcinogenesis through feed-forward

- transcription regulation with estrogen receptor. *Oncogene* 36(39):5497–5511. doi:10.1038/onc.2017.157
28. Sze CC, Shilatifard A (2016) MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer. *Cold Spring Harb Perspect Med* 6(11). doi:10.1101/cshperspect.a026427
 29. Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, Romano-Adesman A, Bjornson RD, Breitbart RE, Brown KK, Carriero NJ, Cheung YH, Deanfield J, DePalma S, Fakhro KA, Glessner J, Hakonarson H, Italia MJ, Kaltman JR, Kaski J, Kim R, Kline JK, Lee T, Leipzig J, Lopez A, Mane SM, Mitchell LE, Newburger JW, Parfenov M, Pe'er I, Porter G, Roberts AE, Sachidanandam R, Sanders SJ, Seiden HS, State MW, Subramanian S, Tikhonova IR, Wang W, Warburton D, White PS, Williams IA, Zhao H, Seidman JG, Brueckner M, Chung WK, Gelb BD, Goldmuntz E, Seidman CE, Lifton RP (2013) De novo mutations in histone-modifying genes in congenital heart disease. *Nature* 498(7453):220–223. doi:10.1038/nature12141
 30. Shilatifard A (2012) The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. *Annu Rev Biochem* 81:65–95. doi:10.1146/annurev-biochem-051710-134100
 31. Ribeiro Franco PI, Rodrigues AP, de Menezes LB, Pacheco Miguel M (2020) Tumor microenvironment components: Allies of cancer progression. *Pathol Res Pract* 216(1):152729. doi:10.1016/j.prp.2019.152729
 32. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauve CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW (2017) Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. *Cancer Cell* 32 (1):42-56 e46. doi:10.1016/j.ccell.2017.06.003
 33. Panigrahi DP, Praharaj PP, Bhol CS, Mahapatra KK, Patra S, Behera BP, Mishra SR, Bhutia SK (2020) The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics. *Semin Cancer Biol* 66:45–58. doi:10.1016/j.semcancer.2019.07.015
 34. Liu YF, Huang ZJ, Cui D, Ouyang GL (2019) The Multiaspect Functions of Periostin in Tumor Progression. *Periostin* 1132:125–136. doi:10.1007/978-981-13-6657-4_13
 35. Gonzalez-Gonzalez L, Alonso J (2018) Periostin: A Matricellular Protein With Multiple Functions in Cancer Development and Progression. *Front Oncol* 8:225. doi:10.3389/fonc.2018.00225
 36. Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, Toda S, Inagaki N, Kurihara Y, Hayashida S, Takeuchi S, Koike K, Ono J, Noshiro H, Furue M, Conway SJ, Narisawa Y, Izuhara K (2012) Periostin promotes chronic allergic inflammation in response to Th2 cytokines. *J Clin Invest* 122(7):2590–2600. doi:10.1172/JCI58978
 37. Zhou WC, Ke SQ, Huang Z, Flavahan W, Fang XG, Paul J, Wu L, Sloan AE, McLendon RE, Li XX, Rich JN, Bao SD (2015) Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. *Nat Cell Biol* 17(2):170–. doi:10.1038/ncb3090

38. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DYR, Chen EI, Lyden D, Bissell MJ (2013) The perivascular niche regulates breast tumour dormancy. *Nat Cell Biol* 15(7):807–. doi:10.1038/ncb2767
39. Prager BC, Xie Q, Bao S, Rich JN (2019) Cancer Stem Cells: The Architects of the Tumor Ecosystem. *Cell Stem Cell* 24(1):41–53. doi:10.1016/j.stem.2018.12.009
40. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H (2011) The brain tumor microenvironment. *Glia* 59(8):1169–1180. doi:10.1002/glia.21136
41. Venere M, Fine HA, Dirks PB, Rich JN (2011) Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. *Glia* 59(8):1148–1154. doi:10.1002/glia.21185
42. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN (2015) Cancer stem cells in glioblastoma. *Genes Dev* 29(12):1203–1217. doi:10.1101/gad.261982.115
43. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Piloizzi E, Larocca LM, Peschle C, De Maria R (2006) Chemotherapy resistance of glioblastoma stem cells. *Cell Death Differ* 13(7):1238–1241. doi:10.1038/sj.cdd.4401872
44. Nagle PW, Plukker JTM, Muijs CT, van Luijk P, Coppes RP (2018) Patient-derived tumor organoids for prediction of cancer treatment response. *Sem Cancer Biol* 53:258–264. doi:10.1016/j.semcancer.2018.06.005
45. Thompson JA, Christensen BC, Marsit CJ (2018) Pan-Cancer Analysis Reveals Differential Susceptibility of Bidirectional Gene Promoters to DNA Methylation, Somatic Mutations, and Copy Number Alterations. *Int J Mol Sci* 19(8). doi:10.3390/ijms19082296
46. Bennett RL, Licht JD (2018) Targeting Epigenetics in Cancer. *Annu Rev Pharmacol Toxicol* 58:187–207. doi:10.1146/annurev-pharmtox-010716-105106

Figures

Figure 1

UTX knockdown influences the proliferation and apoptosis of LN229 cells in a heterotopic xenograft mouse model.

The clinical information data for normal (n=207), LGG (n=518) and GBM (n=163) were obtained and analyzed by GEPIA 2 (<http://gepia2.cancer-pku.cn/#index>). (A, B) The expression level of UTX in normal

tissue, LGG and GBM were present as transcripts per million or log2 transcripts per million. (C) Kaplan-Meier survival analysis was performed for overall survival of LGG and GBM patients. The stable UTX knockdown LN229 cells (1×10^6 per injection) were implanted subcutaneously into the nude mice in the heterotopic xenograft experiment. As negative control, shNC LN229 cells (1×10^6 per injection) were implanted subcutaneously into the nude mice. For Blank group, 1×10^6 of normal LN229 cells were implanted subcutaneously into the nude mice. Mice were killed at 3, 7, 14, and 28 days (the third day after cell inoculation was deemed as 0 d). Five mice of each group were killed at each timepoint, tumors were removed for (D) photograph, the measure of the tumor (E) volumes (length $\times$ width $^2 \times 0.52$) and (F) weights, and (G) Western blotting. (H) Immunoblot quantification for the ratio of cleaved-caspase-3 to pro-caspase-3. (I) Immunoblot quantification for the ratio of cyclin D1 to β -Actin. Data are presented as the mean $\pm$ standard deviation of five independent experiments ($n = 5$). $*p < 0.05$, $**p < 0.01$ versus the shNC group. LGG, Low-grade glioma; GBM, glioblastoma; PCA, principal component analyses; GSEA, gene-set enrichment analysis; GO, gene ontology; DO, disease ontology.

Figure 2

UTX is closely correlated with GBM and regulates tumor-associated genes.

LN229 cells with stable expression of UTX-shRNA (KD-UTX) or scramble shRNA (shNC) were cultured for 3 days before total RNA collection. (A) PCA depicted the results of RNA-seq. (B) Volcano plots showed global differences between shNC and KD-UTX cells. GSEA (C-F), GO enrichment (G), DO analysis (H) and KEGG databases (I) were performed to interpret the RNA-seq results.

Figure 3

UTX knockdown inhibits the expression of extracellular matrix relate genes via increasing the levels of H3K27 methylation

(A) To experimental validation of RNA-seq data, significantly downregulated genes (>1.5 fold) were selected and detected the expression by qRT-PCR. (B) ChIP-qPCR was used to measure the H3K27me2/3

enrichment in the significantly downregulated genes. The genes with a significantly elevated level of H3K27me2/3 were labeled in red. Three days after incubation, the stable UTX knockdown LN229 and cell lysates and culture medium were collected, respectively. (C, D) The level of H3K27me2/3 and histone H3 were detected by Western blot. Data from three independent experiments ($n = 3$) were presented as the ratio of H3K27me2/3 to H3. (E, F) POSTN, COL1A1 and VCAM1 concentration in the culture medium were detected by ELISA. The values are presented as the mean $\pm$ standard deviation of three independent experiments ($n = 3$). $*p < 0.05$ versus shNC group. (G) The intracellular concentration of POSTN, COL1A1, PTHLH, VCAM1 and CPA4 were examined by Western blot. (H, I) Band intensity was quantified and plotted as a ratio of the target protein to β -Actin. The values are presented as the mean $\pm$ standard deviation of three independent experiments ($n = 3$). $*p < 0.05$, $**p < 0.05$ versus shNC group.

Figure 4

POSTN abolishes the effect of UTX knockdown on GBM cell proliferation

(A) The 15 proteins, which are regulated by H3K27me_{2/3}, were screened and protein interactions (grey lines, the confidence score ≥ 0.4) were extracted from the STRING database. (B) The table showed the STRING score of POSTN interacts with other proteins. The infected LN229 and U251 MG cells were

divided into four groups. Blank group: cells were maintained without any treatment; shNC group: cells infected with nonspecific shRNA; KD-UTX group: cells infected with anti-UTX shRNA; KD-UTX +POSTN group: added 2 µg/mL POSTN protein in the knockdown UTX cells culturing medium. (C, D) After culturing 3 days, BrdU-positive cells were determined by immunostaining, and the result was shown as percentages among PI-stained cells. Scale bar 100 µm. (F, G) The proliferation index was determined by cell cycle analysis. (I, J) The colony formation assay was performed to investigate the long-term effect of UTX on proliferation. (E, H and K) Data are presented as the mean ± standard deviation of three independent experiments (n = 3). * $p < 0.05$, ** $p < 0.01$ versus the shNC group. # $p < 0.05$, ## $p < 0.01$ versus the KD-UTX group.

Figure 6

UTX knockdown displays an inhibiting role inpatient-derived GSCs through regulating POSTN

Human GSCs were isolated from three post-surgical patients (GSC02, GSC05 and GSC08). (A) Spheres, 80–120 µm in size were observed after culturing for 5-7 days. The spheres were identified by double immunofluorescent labeling for specific markers CD133 and CD15 (B) or CD44 and nestin (C). Patient-derived GSCs were infected with shNC or KD-UTX lentivirus and divided into four groups. Blank group: cells were maintained without any treatment; shNC group: cells infected with nonspecific shRNA; KD-UTX group: cells infected with anti-UTX shRNA; KD-UTX +POSTN group: added 2 µg/mL POSTN protein in the knockdown UTX cells culturing medium (E-G). The cell viability was quantitatively measured by using a CCK-8 at different time points (1-7 days). After culturing 3 days, cell proliferation was identified by BrdU staining (H) and apoptotic cells were detected by TUNEL staining (I). (J) Quantitative data from three independent experiments (n = 3) were shown as the percentage of BrdU-positive cells in total SOX2-stained cells. (K) Quantitative data from three independent experiments (n = 3) are presented as the percentage of TUNEL-positive cells in the total DAPI cells. * $p < 0.05$, ** $p < 0.01$ versus shNC group; ## $P < 0.01$ versus KD-UTX group. Scale bar, 100 µm (A), 50 µm (D, H); 100 µm (I).

Figure 7

Schematic model of the mechanism by which UTX knockdown regulates glioblastoma progression.

The expression level of UTX is significantly increased in GBM cells (left panel) and results in a low H3K27me2/3 level on the POSTN gene that culminates with activated transcription. POSTN protein could interact with lots of secreted proteins, including COL1A1, PTHLH, CPA4 and VCAM1. These proteins, the important components of the tumor microenvironment, are involved in the proliferation, apoptosis, migration and invasion in GBM cells. Knockdown UTX (right panel) significantly increases the H3K27me2/3 level of the POSTN gene, which in turn represses the transcription of POSTN. Fewer

proteins, especially interaction with POSTN, are secreted to the extracellular matrix and change the tumor microenvironment, thereby inhibiting proliferation, migration and invasion, promoting cell apoptosis, even affecting proliferation and apoptosis of GSCs.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Fig.S1.jpg](#)
- [FIG.S2.jpg](#)
- [Fig.S3.jpg](#)
- [Fig.S4.jpg](#)
- [Fig.S5.jpg](#)
- [SupplementaryFigurelegend.docx](#)
- [SupplementaryTableS2.docx](#)
- [SupplementaryTableS3.docx](#)
- [SupplementaryTableS4.docx](#)